Umbilical cord blood (UCB) is a good source of hematopoietic progenitors with increasing implementation in the clinical transplant setting. This study evaluates the molecular mechanisms of progenitor resistance to apoptosis triggered by Fas cross-linking. CD34+ and lineage-negative progenitors survive short-term ex vivo incubation and are not induced into apoptosis by Fas cross-linking. Furthermore, brief exposure of UCB cells to Fas-ligand for 24–48 h does not impair quantitative severe combine immune deficiency (SCID) reconstitution activity and appears to foster myelomonocyte reconstitution. The transcriptome of Fas receptor-positive CD34+ cells that survived an apoptotic challenge showed significant transcriptional upregulation of caspase-8, mucosa-associated lymphoid tissue lymphoma translocation gene-1 (MALT1), HtrA2, and GSK3β in addition to higher levels of c-FLICE inhibitory protein (FLIP), Bcl-2, and cytosolic inhibitor of apoptosis protein (cIAP) in all Fas-positive cells. Most prominent is the transcriptional upregulation of several key components the NFκB1 pathway including the membrane receptors TGF-β, interleukin-1 (IL-1), and TCR, the associated factor TNF receptor-associated factor-6 (TRAF6), and the converting enzymes TGF-β-activated kinase-1 (TAK1), double-stranded RNA-activated protein kinase (PKR), and α-catalytic subunit of IκB kinase (IKKα), that promote activation and nuclear translocation of this transcription factor. These data indicate that hematopoietic progenitors are not insensitive to apoptosis but are actively shielded from the extrinsic and intrinsic apoptotic pathways. This may occur through inherent transcriptional upregulation of the entire NFκB pathway in the presence of competent apoptotic signaling.
Get full access to this article
View all access options for this article.
References
1.
LenardoM, ChanKM, HornungF, McFarlandH, SiegelR, WangJ, SiegelR, WangJ and ZhengL. (1999). Mature T lymphocyte apoptosis—immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol, 17:221–253.
2.
NihoY and AsanoY. (1998). Fas/Fas ligand and hematopoietic progenitor cells. Curr Opin Hematol, 5:163–165.
3.
MaciejewskiJ, SelleriC, AndersonS and YoungNS. (1995). Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 85:3183–3190.
4.
NagafujiK, ShibuyaT, HaradaM, MizunoS, TakenakaK, MiyamotoT, OkamuraT, GondoH and NihoY. (1995). Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood, 86:883–889.
5.
BarcenaA, ParkSW, BanapourB, MuenchMO and MechetnerE. (1996). Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood, 88:2013–2025.
6.
FukudaS and PelusLM. (2001). Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34 cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood, 98:2091–2100.
7.
KimH, WhartenbyKA, GeorgantasRW, WingardJ and CivinCI. (2002). Human CD34 Hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells, 20:174–182.
8.
PyattDW, StillmanWS, YangY, GrossS, ZhengHJ and IronsRD. (1999). An essential role for NF-{kappa}B in human CD34+ bone marrow cell survival. Blood, 93:3302–3308.
9.
StahnkeK, HeckerS, KohneE and DebatinKM. (1998). CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol, 26:844–850.
10.
SahekiK, FujimoriY, TakemotoY and KakishitaE. (2000). Increased expression of Fas (APO-1, CD95) on CD34+ haematopoietic progenitor cells after allogeneic bone marrow transplantation. Br J Haematol, 109:447–452.
11.
YoungJC, LinK, TravisM, HansteenG, AbitorabiA, SirenkoO, AbitorabiA, SirenkoO, MurrayL and HillB. (2001). Investigation into an engraftment defect induced by culturing primitive hematopoietic cells with cytokines. Cytotherapy, 3:307–320.
12.
BarcenaA, MuenchM, SongKS, OhkuboT and HarrisonMR. (1999). Role of CD95/Fas and its ligand in the regulation of the growth of human CD34++ CD38− fetal liver cells. Exp Hematol, 27:1428–1439.
13.
JosefsenD, MyklebustJH, LynchDH, StokkeT, BlomhoffHK and SmelandEB. (1999). Fas ligand promotes cell survival of immature human bone marrow CD34+CD38− hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol, 27:1451–1459.
14.
DybedalI, YangL, BryderD, Aastrand-GrundstromI, LeanderssonK and JacobsenSE. (2003). Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression. Blood, 102:118–126.
15.
AskenasyN, YolcuES, YanivI and ShirwanH. (2005). Fas-ligand as a double-edged immunomodulator to induce transplantation tolerance. Blood, 105:1396–1404.
16.
GlimmH, OhIH and EavesCJ. (2000). Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood, 96:4185–4193.
17.
MoriT, NishimuraT, IkedaY, HottaT, YagitaH and AndoK. (1998). Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression. Blood, 92:101–107.
18.
IwasakiT, HamanoT, SahekiK, KuroiwaT, KataokaY, TakemotoY, OgataA, FujimotoJ and KakishitaE. (2000). Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway. Immunology, 99:94–100.
19.
Pearl-YafeM, YolcuES, SteinJ, KaplanO, ShirwanH, YanivI and AskenasyN. (2007). Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol, 35:1601–1612.
20.
Pearl-YafeM, SteinJ, YolcuES, FarkasDL, ShirwanH, YanivI and AskenasyN. (2007). Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells, 25:3194–3203.
21.
Pearl-YafeM, YolcuES, SteinJ, KaplanO, YanivI, Shirwan H and AskenasyN. (2007). Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells, 25:1448–1455.
22.
WhartenbyKA, StraleyEE, KimH, RackeF, TanavdeV, GorskiKS, ChengL, PardollDM and CivinCI. (2002). Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood, 100:3147–3154.
23.
Pearl-YafeM, MizrahiK, SteinJ, YolcuES, KaplanO, ShirwanH, YanivI and AskenasyN. (2010). Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells, 28:1270–1280.
24.
MizrahiK, SteinJ, YanivI, KaplanO and AskenasyN. (2012). TNF-α has tropic rather than apoptotic activity in human hematopoietic progenitors: involvement of TNF receptor-1 and caspase-8. Stem Cells, 31:156–166.
25.
MizrahiK, SteinJ, Pearl-YafeM, KaplanO, YanivI and AskenasyN. (2010). Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation. Leukemia, 24:1325–1334
26.
SchuurhuisGJ, MuijenMM, OberinkJW, de BoerF, OssenkoppeleGJ and BroxtermanHJ. (2001). Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants. Bone Marrow Transplant, 27:487–498.
27.
WangLS, LiuHJ, XiaZB, BroxmeyerHE and LuL. (2000). Expression and activation of caspase-3/CPP32 in CD34(+) cord blood cells is linked to apoptosis after growth factor withdrawal. Exp Hematol, 28:907–915.
28.
LiuB, BuckleySM, LewisID, GoldmanAI, WagnerJE and van der LooJC. (2003). Homing defect of cultured human hematopoietic cells in the NOD/SCID mouse is mediated by Fas/CD95. Exp Hematol, 31:824–832.
29.
BegAA and BaltimoreD. (1996). An essential role for NF-κB in preventing TNF-α induced cell death. Science, 274:782–784.
30.
LiuZ-G, HuH, GoeddelDV and KarinM. (1996). Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis, while NF-B activation prevents cell death. Cell, 87:565–576.
31.
Van AntwerpDJ, MartinSJ, KafriT, GreenDR and VermaIM. (1996). Suppression of TNF-induced apoptosis by NF-κB. Science, 274:787–789.
32.
CauxC, FavreC, SaelandS, DuvertV, DurandI, MannoniP and BanchereauJ. (1991). Potentiation of early hematopoiesis by tumor necrosis factor-alpha is followed by inhibition of granulopoietic differentiation and proliferation. Blood, 78:635–644.
33.
DomenJ, CheshierSH and WeissmanIL. (2000). The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med, 191:253–264.
34.
BudihardjoI, OliverH, LutterM, LuoW and WangX. (1999). Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol, 15:269–290.
35.
van LooG, SaelensX, van GurpM, MacFarlaneM, MartinSJ and VandenabeeleP. (2002). The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ, 9:1031–1042.
36.
MartinsLM, IaccarinoI, TenevT, GschmeissnerS, TottyNF, LemoineNR, SavopoulosJ, GrayCW, CreasyCL, DingwallC and DownwardJ. (2002). The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem, 277:439–444.
37.
KieperN, HolmströmKM, CiceriD, FieselFC, WolburgH, ZivianiE, WhitworthAJ, MartinsLM, KahlePJ and KrügerR. (2010). Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. Exp Cell Res, 316:1213–1224.
38.
DarnayBG, NiJ, MoorePA and AggarwalBB. (1999). Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem, 274:7724–7731.
39.
DengL, WangC, SpencerE, YangL, BraunA, YouJ, SlaughterC, PickartC and ChenZJ. (2000). Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell, 103:351–361.
40.
TakaesuG, KishidaS, HiyamaA, YamaguchiK, ShibuyaH, IrieK, Ninomiya-TsujiJ and MatsumotoK. (2000). TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell, 5:649–658.
41.
JiangZ, Ninomiya-TsujiJ, QianY, MatsumotoK and LiX. (2002). Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol, 22:7158–7167.
42.
WangC, DengL, HongM, AkkarajuGR, InoueJ and ChenZJ. (2001). TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature, 412:346–351.
43.
ZhangX, ZhangJ, ZhangL, van DamH and Ten DijkeP. (2013). UBE2O negatively regulates TRAF6-mediated NF-κB activation by inhibiting TRAF6 polyubiquitination. Cell Res, 23:366–377.
44.
Zamanian-DaryoushM, MogensenTH, DiDonatoJA and WilliamsBR. (2000). NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol, 20:1278–1290.
45.
SenftlebenU, CaoY, XiaoG, GretenFR, KrähnG, BonizziG, ChenY, HuY, FongA, SunSC and KarinM. (2001). Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293:1495–1499.
46.
HoffmannA and BaltimoreD. (2006). Circuitry of nuclear factor kappaB signaling. Immunol Rev, 210:171–186.
47.
HoffmannA, LevchenkoA, ScottML and BaltimoreD. (2002). The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science, 298:1241–1245.
48.
De MolfettaGA, Lucíola ZanetteD, Alexandre PanepucciR, Dos SantosAR, da SilvaWA and Antonio ZagoM. (2010). Role of NFKB2 on the early myeloid differentiation of CD34+ hematopoietic stem/progenitor cells. Differentiation, 80:195–203.
49.
MehlenP, Schulze-OsthoffK and ArrigoAP. (1996). Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. J Biol Chem, 271:16510–16514.
50.
PypeS, DeclercqW, IbrahimiA, MichielsC, Van RietschotenJG, DewulfN, de BoerM, VandenabeeleP, HuylebroeckD and RemacleJE. (2000). TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation. J Biol Chem, 275:18586–1893.
51.
WildeJI and WatsonSP. (2001). Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other?. Cell Signal, 13:691–701.
52.
PanepucciRA, CaladoRT, RochaV, Proto-SiqueiraR, SilvaWA and ZagoMA. (2007). Higher expression of transcription targets and components of the nuclear factor-kappaB pathway is a distinctive feature of umbilical cord blood CD34+ precursors. Stem Cells, 25:189–196.
53.
QinY, AuhS, BlokhL, LongC, GagnonI and HamannKJ. (2007). TNF-alpha induces transient resistance to Fas-induced apoptosis in eosinophilic acute myeloid leukemia cells. Cell Mol Immunol, 4:43–52.
54.
PomerantzJL and BaltimoreD. (2010). Two pathways to NF-kappaB. Mol Cell, 10:693–695.
55.
ShihVF, TsuiR, CaldwellA and HoffmannA. (2011). A single NFκB system for both canonical and non-canonical signaling. Cell Res, 21:86–102.
56.
PellegriniM, BathS, MarsdenVS, HuangDC, MetcalfD, HarrisAW and StrasserA. (2005). FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. Blood, 106:1581–1589.
57.
WangCY, MayoMW, KornelukRG, GoeddelDV and BaldwinAS. (1998). NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281:1680–1683.
58.
HuangDC, TschoppJ and StrasserA. (2000). Bcl-2 does not inhibit cell death induced by the physiological Fas ligand: implications for the existence of type I and type II cells. Cell Death Differ, 7:754–755.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
